Abiopharma

🔍 Roman Michael F (Executive)

Company: ABBOTT LABORATORIES (ABT)

Report Date: 2026-04-24

Detailed Transactions and Holdings:

• Acquired 2,286 shares of Common shares without par value (Direct)
  Date: 2026-04-24 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,764.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).